

UCLA

UCLA Previously Published Works

Title

The Association of Oncology Provider Density With Black-White Disparities in Cancer Mortality in US Counties.

Permalink

<https://escholarship.org/uc/item/9bh6v100>

Authors

Zhang, Yuehan
Leifheit, Kathryn
Lee, Kimberley
[et al.](#)

Publication Date

2024

DOI

10.1177/10732748241244929

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial License, available at <https://creativecommons.org/licenses/by-nc/4.0/>

Peer reviewed

The Association of Oncology Provider Density With Black-White Disparities in Cancer Mortality in US Counties

Cancer Control
Volume 31: 1–10
© The Author(s) 2024
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/10732748241244929
journals.sagepub.com/home/ccx



Yuehan Zhang, ScM, PhD¹, Kathryn M. Leifheit, PhD², Kimberley T. Lee, MD, MHS³, Roland J. Thorpe Jr., PhD^{4,5}, Darrell J. Gaskin, PhD^{4,6}, and Lorraine T. Dean, ScD^{1,6,7} 

Abstract

Background: Black-White racial disparities in cancer mortality are well-documented in the US. Given the estimated shortage of oncologists over the next decade, understanding how access to oncology care might influence cancer disparities is of considerable importance. We aim to examine the association between oncology provider density in a county and Black-White cancer mortality disparities.

Methods: An ecological study of 1048 US counties was performed. Oncology provider density was estimated using the 2013 National Plan and Provider Enumeration System data. Black:White cancer mortality ratio was calculated using 2014–2018 age-standardized cancer mortality rates from State Cancer Profiles. Linear regression with covariate adjustment was constructed to assess the association of provider density with (1) Black:White cancer mortality ratio, and (2) cancer mortality rates overall, and separately among Black and White persons.

Results: The mean Black:White cancer mortality ratio was 1.12, indicating that cancer mortality rate among Black persons was on average 12% higher than that among White persons. Oncology provider density was significantly associated with greater cancer mortality disparities: every 5 additional oncology providers per 100 000 in a county was associated with a .02 increase in the Black:White cancer mortality ratio (95% CI: .007 to .03); however, the unexpected finding may be explained by further analysis showing that the relationship between oncology provider density and cancer mortality was different by race group. Every 5 additional oncologists per 100 000 was associated with a 1.6 decrease per 100 000 in cancer mortality rates among White persons (95% CI: –3.0 to –.2), whereas oncology provider density was not associated with cancer mortality among Black persons.

Conclusion: Greater oncology provider density was associated with significantly lower cancer mortality among White persons, but not among Black persons. Higher oncology provider density alone may not resolve cancer mortality disparities, thus attention to ensuring equitable care is critical.

¹Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

²Department of Health Policy & Management, UCLA Fielding School of Public Health, Los Angeles, CA, USA

³Departments of Breast Oncology and Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA

⁴Hopkins Center for Health Disparities Solutions, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

⁵Department of Health Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

⁶Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

⁷Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

Corresponding Author:

Lorraine T. Dean, Johns Hopkins University, 615 N Wolfe St, Room E6650, Baltimore, MD 21205, USA.

Email: lori.dean@jhu.edu



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and

Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

Plain language summary

Our study provides timely information to address the growing concern about the need to increase oncology supply and the impact it might have on racial disparities in cancer outcomes. This analysis of counties across the US is the first study to estimate the association of oncology provider density with Black-White racial disparities in cancer mortality. We show that having more oncology providers in a county is associated with significantly lower cancer mortality among the White population, but is not associated with cancer mortality among the Black population, thereby leading to a disparity. Our findings suggest that having more oncology providers alone may be insufficient to overcome existing disadvantages for Black patients to access and use high-quality cancer care. These findings have important implications for addressing racial disparities in cancer outcomes that are persistent and well-documented in the US.

Keywords

oncology provider density, racial disparities, cancer, mortality, workforce

Received September 14, 2023. Received revised February 29, 2024. Accepted for publication February 8, 2024.

Introduction

Black-White racial disparities in cancer mortality are persistent and well-documented in the United States (US).¹ Disparities in outcomes have primarily focused on individual-level patient risk factors, such as greater tobacco use, and structural barriers, such as lower rates of access to cancer screenings for Black persons than White persons,²⁻⁶ with less emphasis on the contexts in which these disparate outcomes occur.⁷⁻¹² In response to the American Society of Clinical Oncology's prediction of a shortage of 2258 oncologists by year 2025,¹³ there is growing concern about oncologist supply and the impact it might have on cancer disparities.

Oncology provider density, as 1 measure of oncology care access, has the potential to improve cancer outcomes and mortality. Greater density of providers may facilitate timely diagnosis and treatment, while also giving more opportunities for patients to access care. In the US, 1 recent study estimated that median survival of cancer patients in counties with lowest oncology provider density was significantly lower (8 vs 11 months) than patients in counties with highest oncology provider density, after controlling for patient demographics and use of radiation treatment.¹⁴ Other studies have examined general provider density, using Health Professional Shortage Areas (HPSA), on specific aspects of cancer treatment. For example, patients living partially (vs. completely) in a HPSA had greater adherence to oral anti-cancer medications for breast cancer survivors,^{15,16} yet neither study focused on racial disparities. A greater number of locally available providers could reduce structural barriers to early diagnosis, timely treatment, and adherence, potentially improving survival among Black cancer patients, who are more likely to be affected by these barriers; yet the relationship between oncology provider density and racial disparities in cancer mortality has not been explored empirically.

In this ecological analysis, our goal was to examine the role of oncology provider density in Black-White cancer

disparities in the US. We hypothesized that higher oncology density in a county, as a proxy for oncologist availability, is associated with smaller Black-White racial disparities in cancer mortality.

Materials and Methods

This ecological observational study used publicly available, de-identified data. The Institutional Review Board office determined that this study did not require IRB oversight.

Data Sources and Measures

Dependent Variables. The primary outcome measure was the Black-White cancer mortality ratio in the US based on mortality rate data from Black and White persons in 2014-2018, from State Cancer Profiles. We calculated the mortality ratio outcome as the age-standardized cancer mortality rates among the Black population divided by rates among the White population in the same county. A ratio >1 represents higher cancer mortality rates for Black vs White persons while <1 represents lower cancer mortality rates for Black vs White persons. Secondary outcomes were age-standardized, county-level cancer mortality rates, including deaths from all cancers. Case counts <16 are suppressed in State Cancer Profiles data, therefore counties with <16 race-specific deaths (either due to low mortality rates or small population size) were excluded from our analyses. Puerto Rico was missing cancer incidence and mortality data for Black and White populations and was excluded in this analysis.

Independent Variables. Oncology provider density was defined as the number of oncologists per 100 000 population in a county obtained from the publicly available 2013 Centers for Medicare & Medicaid Services (CMS) National Plan and Provider Enumeration System (NPPES). Providers

specializing in oncology and practicing in the US were identified using provider taxonomy code ([Supplemental Table 1](#)). Provider practice addresses were geocoded to US county using ArcGIS. Total population counts for each county came from the 2013-2017 American Community Survey (ACS).

Covariates. We selected covariates hypothesized a priori to be potential confounders, including county-level covariates: 2013-2017 State Cancer Profiles Black-White cancer incidence ratio¹⁷; 2013-2017 ACS variables for income inequality (Gini index ranging from 0 [perfect equality] to 1 [maximal inequality]), percent of population that is Black, percent of population with health insurance coverage; metropolitan status based on United States Department of Agriculture (USDA) Rural-Urban Continuum Codes (values 1-3 were coded as metro areas; values 4-9 were coded as non-metro areas); and US Census Bureau census region (Northeast, Midwest, West, and South). Black-White cancer incidence ratio was constructed to account for geographic variation in risk factor profiles and cancer prevention practices. This variable was defined as age-standardized cancer incidence rates among the Black population divided by rates among the White population. As with mortality data, case counts <16 were suppressed, leading to incomplete incidence data. Given our age-standardized rates, we did not include age in our models. We did not include sex in our models, given that some cancers are sex-specific.

Calculation. Continuous variables were converted to z-scores and included in the regression models. Linear regression models were constructed to quantify the association of county-level oncology provider density with subsequent Black-White cancer mortality ratio, adjusting for the covariates listed above. Next, linear regression was used to quantify the association of oncology provider density with cancer mortality rates, overall, and separately among Black and White populations. In models of cancer mortality rates, we adjusted for cancer incidence rates (overall, among Black and White persons, respectively), Gini index, percent of population that is Black (only in the model of overall cancer mortality rates), health insurance coverage, metropolitan status, and census region. These race-specific analyses allowed us to explore whether oncology provider density might have a different association with cancer mortality by race. Furthermore, predicted cancer mortality rates by oncology provider density were estimated after fitting multivariable linear regression models adjusted for the covariates listed above. We conducted sensitivity analyses with oncology provider density modeled as a categorical variable, which allowed us to explore potential non-linearity in its association with the outcomes.

Linear regression was chosen for modeling age-standardized cancer mortality rates to control for potential confounding by age, instead of Poisson regression which is commonly used to model crude cancer mortality rates. There

was little evidence of clustering of counties within state (intra-class correlation <.15 for all models), thus standard errors were not adjusted for clustering by state. Statistical significance was determined by a 2-sided *P*-value <.05. Analyses were conducted using STATA/IC 16.1, R version 4.0.2, and SAS University Edition.

Results

Of 3142 US counties, we identified 1054 counties with complete data on race-specific cancer incidence and mortality rates. We excluded 5 outlier counties with oncology provider density >40 per 100 000 population (Suffolk County, MA; Durham County, NC; Orange County, NC; New York County, NY; Salem City, VA) and 1 county (Union County, FL) with skewed overall cancer mortality (455 per 100 000) and incidence rates (1144 per 100 000). The analytic sample comprised 1048 US counties from 40 states, the District of Columbia, representing 75% of total US population. Compared to the full set of U.S. counties, our analytic set included counties that had higher population density and higher percent of the population that is Black and were more likely to be a metropolitan county and from the Southern US ([Table 1](#)).

There were 20 935 oncology providers practicing in the US in 2013 ([Supplemental Table 1](#)), including 20 352 oncology physicians and 403 oncology nurses and physician's assistants. Oncology provider density was higher in the analytic sample compared to overall US counties (median value: 2 vs 0 per 100 000; [Table 1](#)). About one-third of overall US counties had at least 1 oncologist compared with 56% (592 counties) in the analytic sample. Overall, there were substantial variations in geographic distribution of oncologists throughout US counties ([Figure 1A](#)). At the census region level, 71.4% of counties in the Northeast had at least 1 oncologist, higher than the proportions in the West (34.8%), South (30.9%) and Midwest (26.5%). Within a region, oncology provider density varied by state and county, suggesting that oncology provider density may be impacted by local, state, and regional-level factors. [Figure 1B](#) shows the distribution of cancer mortality ratio comparing Black persons to White persons. In the 1048 counties studied, the mean cancer mortality ratio was 1.12, indicating that cancer mortality rate among Black persons was on average 12% higher than that among White persons. Cancer mortality ratio was heterogeneously distributed across counties, ranging from .44 (in Coryell County, TX) to 2.03 (District of Columbia).

Oncology provider density was significantly associated with higher Black-White cancer mortality ratio. In the adjusted model, every standard deviation (SD) increase in oncology provider density (~5 per 100 000) in a county was associated with a .02 increase in cancer mortality ratio (95% confidence interval [CI]: .007 to .03; [Table 2](#)). In addition to oncology provider density, counties with higher Gini index and higher Black-White cancer incidence ratio had significantly higher cancer mortality ratio ([Table 2](#)).

Table 1. Characteristics of 3142 US Counties Overall and 1048 US Counties Included in the Analysis.

No. (%)	All US Counties	Analytic Counties
Counties & Washington DC	3142 (100%)	1048 (33%)
States	51 (100%)	41 (80%) ^a
Total population (million)	321.0 (100%)	242.0 (75%)
County population, median (IQR) ^b	25 692 (10 942, 67 477)	68 505 (25 646, 212 383)
Population density per square mile, median (IQR)	45.5 (17.8, 119.5)	128.1 (47.2, 377.9)
Oncologists per 100 000 population, median (IQR)	0 (0, 3)	2 (0, 5)
Having at least 1 oncologist	1031 (33%)	592 (56%)
Gini index, median (IQR)	.4 (.4, .5)	.5 (.4, .5)
Percent population that is Black, median (IQR)	2.2 (.6, 10.3)	17.2 (8.2, 32.8)
Percent of health insurance coverage, median (IQR)	89.7 (86.2, 92.7)	88.1 (85.6, 91.1)
Metropolitan county	1166 (37%)	653 (62%)
Region		
Northeast	217 (7%)	88 (8%)
Midwest	1055 (34%)	105 (10%)
South	1422 (45%)	797 (76%)
West	448 (14%)	58 (6%)

^a10 states were excluded because these counties either did not have data on Black-White cancer incidence or mortality disparity or counties had oncology provider density >40 per 100 000: ID, KS, ME, MN, MT, ND, NH, SD, VT, WY, and PR.

^bIQR = interquartile range.

To investigate why oncology provider density was associated with higher Black-White cancer mortality ratio, we modeled the association of oncology provider density with cancer mortality rates, overall and separately among Black and White populations (Figure 2; Supplemental Table 2). After adjusting for covariates, an increase of oncology provider density by 1 SD was associated with a 1.5 decrease per 100 000 (95% CI: −2.7, −.3) in overall cancer mortality rates, and a 1.6 decrease per 100 000 (95% CI: −3.0, −.2) in cancer mortality rates among White population. In contrast, among Black population, oncology provider density was not significantly associated with cancer mortality rates (.9 per 100 000, 95% CI: −1.2, 2.9). Of note, income inequality appeared to have a differential association with cancer mortality between White and Black populations (Supplemental Table 2). An increase of Gini index by 1 SD (.03) was associated with lower cancer mortality among White population (−1.7, 95% CI: −3.1 to −.4); conversely it was associated with higher cancer mortality among Black population (2.0, 95% CI: .002 to 4.1).

To contextualize these results, we next predicted the cancer mortality rates among Black and White populations by oncology provider density, adjusting for covariates (Figure 3). In counties with 5 oncologists per 100 000, the predicted cancer mortality rates were 194.0 per 100 000 (95% CI: 183.5 to 204.6) for Black population and 162.2 per 100 000 (95% CI: 155.2 to 169.1) for White population. These mortality disparities were predicted to be greater among counties with more oncologists. In counties with 15 oncologists per 100 000, the predicted cancer mortality rates were 202.6 per 100 000 (95% CI: 171.3 to 233.8) for Black population and 146.3 per 100 000 (95% CI: 125.7 to 166.8) for White population.

Results from sensitivity analyses where oncology provider density was modeled as a categorical variable were similar to primary results (Supplemental Tables 3 and 4).

Discussion

Contrary to our initial hypothesis, higher oncology density in US counties was associated with greater income inequality, Black-White cancer incidence disparities, and Black-White mortality disparities. Upon further inspection, this result was driven by differential relationships between oncology provider density and cancer mortality by race group: a higher density of oncology providers in a county was associated with lower mortality rates among White persons, but not among Black persons. These findings may also indicate that oncology provider density data are a good proxy for oncology service access and use among White persons but not Black persons. To our knowledge, this is the first study to assess the association of oncology provider density and racial disparities in cancer outcomes.

Our findings of better cancer outcomes among White persons in areas with higher oncology provider density were consistent with results of previous studies in the US.^{14,18} In studies of SEER data, overall survival is higher¹⁴ and prostate cancer mortality rates were lower¹⁸ in areas with higher provider density. Similarly, higher density of urologists and dermatologists have been associated with lower mortality rates for urologic cancer and melanoma, respectively.^{19,20} Our research adds to this body of literature by illustrating that the potential protective impact of higher oncologist supply is not equally reaching Black persons.




Figure I. Map of oncology provider density per 100 000 in 2013 (Panel A) and cancer mortality ratio comparing Black to White persons from 2014-2018 (Panel B) for US counties and the District of Columbia. *Note.* In Panel a, oncologist count data came from the 2013 CMS National Plan and Provider Enumeration System. In Panel b, Black-White cancer mortality ratio was defined as age-standardized cancer mortality rate among Black persons of a given county divided by the rate among White persons. Cancer mortality rates included all cancer sites, all ages and sexes, from 2014 to 2018, provided by the State Cancer Profiles. Greater inequity in cancer mortality rate was depicted by red color (higher cancer mortality rate for Black vs White persons) or blue color (lower cancer mortality rate for Black vs White persons). Equity in cancer mortality rate was depicted by white color. (A) total of 1075 counties had complete data for cancer mortality ratio. Cancer mortality ratio was unavailable for 2067 counties, depicted by grey color, where race-specific cancer mortality rates were unavailable on the State Cancer Profiles. R (version 4.0.2) was used to generate the figure.

We found that oncology provider density was not associated with improved cancer mortality among Black persons. This finding is consistent with the diminishing return hypothesis, which in the context of health suggests that Black persons receive diminished health returns from resources and assets compared with their White counterparts.^{21,22} Several potential mechanisms may underlie this finding. First, high oncology provider density does not necessarily reflect access to high-quality cancer care because of race-based segregation that has led to unequal geographic distribution of high-quality cancer care facilities. For example, in Chicago, 1 of the most persistently racially segregated cities in the US, hospitals with an American College of Surgeons Commission on Cancer


Center designation were disproportionately located in predominantly White neighborhoods, while only 2 of 12 hospitals with American College of Surgeons designation were located in predominantly Black neighborhoods.²³ Therefore, despite the oncology care available, Black patients living in these neighborhoods might have been more likely to encounter obstacles to high-quality cancer care compared with their White counterparts.

Aside from unequal geographic distribution of facilities providing high-quality cancer care, Black patients may encounter challenges in accessing care at high-quality facilities. In the US, Black patients remain less likely to have insurance coverage than White patients,²⁴ and are

Table 2. Association of Oncology Provider Density (per 100 000) With County-Level Cancer Mortality Ratio Comparing Black to White Persons in the US, Adjusting for Covariates.

Variable ^a	Change in Cancer Mortality Ratio (95%CI)	P Value
Oncologists per 100 000 population per 1 SD increase	.019 (.007, .031)	.002
Gini index per 1 SD increase	.023 (.011, .036)	<.001
Cancer incidence ratio (Black:White) per 1 SD increase	.110 (.099, .120)	<.001
Percent of population that is Black per 1 SD increase	.006 (–.007, .019)	.35
Percent of health insurance coverage per 1 SD increase	.009 (–.004, .022)	.17
Metropolitan county	.017 (–.009, .043)	.20
Region		
South	Reference	
Northeast	–.025 (–.069, .019)	.26
Midwest	.022 (–.017, .062)	.26
West	.013 (–.037, .063)	.62

^aContinuous variables were converted to z-scores, and their coefficients shown in the table represent the change in cancer mortality ratio associated with 1 standard deviation (SD) increase in the independent variable.

**Figure 2.** Association of oncology provider density (per 100 000) with age-standardized cancer mortality rates (per 100 000) overall and among Black and White persons in the US. Note. Estimate represents the change in age-standardized cancer mortality rate per 100 000 associated with 1 standard deviation increase in oncology provider density per 100 000. Estimate was adjusted for age-standardized cancer incidence rate per 100 000 (overall and among Black and White persons, respectively), Gini index, percent of population that is Black (only in the model of overall cancer mortality rates), percent of health insurance coverage, metropolitan status, and census region. Error bars indicate 95% confidence interval (CI). R (version 4.0.2) was used to generate the figure.

disproportionally treated at safety-net hospitals which provide healthcare to patients irrespective of their insurance status. While some studies suggest that safety-net hospitals had similar levels of performance on quality measures compared with other hospitals, studies in oncology care and others have reported an association of safety-net hospitals with poorer performance, longer hospital stays, increased rates of mortality and surgical complications than non-safety-net hospitals.²⁵⁻²⁷

In addition, Black patients may be treated by different providers and experience different referral patterns.²⁸⁻³⁰ In an early study of Medicare beneficiaries, Bach and colleagues reported that primary care providers treating Black patients were less well trained, and were more likely to face challenges in accessing high quality healthcare resources for their patients.²⁹ Differences in providers' qualification leading to

differential referral patterns may in part explain disparities in the number of subspecialist referrals/visits,³¹⁻³³ quality of the treatment received,³⁴ and quality of the hospital where subsequent care is given³⁵ between Black and White cancer patients.

Disparities in cancer outcomes between Black and White persons may still occur due to cumulative challenges that Black persons experience along the cancer care continuum. In the US, Black persons are more likely to be diagnosed at more advanced stages than White persons for breast cancer, lung cancer, colorectal cancer, and prostate cancer^{2,36}; stage at diagnosis is 1 of the most influential factors contributing to racial disparities in cancer survival.³⁶ Among patients with cancer, Black persons were more likely to encounter treatment delays and receive different treatment regimens and examinations compared with White persons.³⁷⁻⁴³ For example, in an




Figure 3. Predicted cancer mortality rates per 100 000 among Black and White persons by oncology provider density in the US. Note. Predicted cancer mortality rates were estimated after fitting a multivariable linear regression model for the outcome of cancer mortality rates among Black and White persons separately, adjusting for Gini index, cancer incidence rate (among Black and White persons, respectively), percent of health insurance coverage, metropolitan status, and census region. Error bar indicates 95% confidence interval for the predicted estimates. Excel was used to generate the figure.

observational study of breast cancer patients, Black women were more likely to experience delayed initiation of adjuvant chemotherapy, which was associated with poor outcomes.³⁸ During and after cancer treatment, Black-White racial disparities in health-related quality of life have also been documented.⁴⁴ It is possible that Black patients who are disproportionately exposed to discrimination and barriers to health care⁴⁵ may be more vulnerable to adverse effects of cancer diagnosis and treatment, leading to worse survival.

Given the growing concern about the need to increase oncology provider density, the healthcare community must be careful to think about how to also optimize equity of care. As suggested by our findings, greater oncologist supply alone may be insufficient to overcome existing systematic disadvantages for Black persons to access and use high-quality cancer care. In fact, increasing oncology provider density while failing to account for the context of overarching health inequities may potentially further widen the gaps in cancer mortalities between Black and White persons. Collective efforts within and among institutions are needed to identify solutions to address structural racism that is a root cause of unequal distribution of high-quality healthcare resources and to promote equity in cancer care delivery.

Our study has a few limitations. First, we used a single source, NPPES data, to generate oncology counts; however, NPPES has similar levels of accuracy as other data sources (e.g., SK&A and American Medical Association Physician Masterfile)⁴⁶ and our estimated oncologist count is mostly consistent with the figures previously published.⁴⁷⁻⁴⁹ Our estimate may have been an undercount, however, since we could not account for non-secondary provider practice locations and the oncologist workforce has been slowly increasing since 2013,⁴⁷ and cancer surgeons may have been listed under some other surgical taxonomy code other than oncology (e.g.,

thoracic surgery, general surgery). County-level oncology provider density is an imperfect measure of access, especially in areas where patients may cross county borders for care. Second, while oncology provider density was used as a proxy for the supply for oncology services, we did not consider the demand for oncology services, which impacts the availability of oncology services. However, we adjusted for several factors associated with the demand including cancer incidence, insurance coverage, and metropolitan status. Third, we focused on mortality of all cancers to maximize the sample size of counties with race-specific mortality rates. The estimated association of oncology provider density with cancer mortality may not be generalizable to every type of cancer, which has its own natural history and treatment modalities. Fourth, we focused on Black-White disparities in cancer mortality because these are well-characterized in the literature and there were enough counties with publicly available data on Black and White cancer mortality for the analyses. However, disparities exist for certain cancers that affect other racial/ethnic groups,⁶ such as higher incidence of lung cancer among never-smoking Asian American, Native Hawaiian, and Pacific Islander females compared with non-White females.⁵⁰ Future research should investigate the role of oncology provider density in these health disparities. Fifth, due to data unavailable in counties in ten states that did not have sufficient data to conduct analysis, our findings may not be generalizable to all counties across the country, particularly ones in the Midwest and parts of New England. Last, our analysis sought to identify the role of oncology provider density in cancer disparities therefore an ecological study design was appropriate; however, inferences about individual-level patient outcomes should be avoided.

Conclusion

In conclusion, we demonstrate that higher oncology provider density is associated with lower cancer mortality rates among White persons, but not among Black persons. Increasing oncology provider density alone may not resolve cancer mortality disparities, thus attention to ensuring equitable cancer care remains critical even if oncology provider density grows.

Appendix

Abbreviations

ACS	American Community Survey
CMS	Centers for Medicare & Medicaid Services
HPSA	Health Professional Shortage Areas
NPPES	National Plan and Provider Enumeration System
SD	Standard Deviation
US	United States
USDA	United States Department of Agriculture

Author Contributions

Conceptualization: All authors

Methodology: All authors

Writing – original draft: All authors

Writing – review & editing: All authors

Data curation: Zhang, Leifheit

Formal Analysis: Zhang, Leifheit

Visualization: Zhang, Leifheit

Funding acquisition: Gaskin, Thorpe

Resources: Gaskin, Thorpe

Project administration: Dean

Supervision: Dean

Authors' Note

Abstract was presented as a virtual poster presentation at 14th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, October 2021.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Agency for Healthcare Research and Quality (2T32HS000046) and National Institutes of Health (U54MD000214). The National Institute On Minority Health And Health Disparities of the National Institutes of Health, and the Agency for Healthcare Research and Quality played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Ethical Statement

Ethics Approval

This study used publicly available, de-identified data. The Institutional Review Board office determined that this study did not require IRB oversight.

ORCID iD

Lorraine T. Dean  <https://orcid.org/0000-0002-2272-2755>

Data Availability Statement

The datasets generated during and/or analyzed during the current study are available in the public domain: CMS National Plan and Provider Enumeration System (https://download.cms.gov/nppes/NPI_Files.html), State Cancer Profiles (<https://statecancerprofiles.cancer.gov/data-topics/incidence.html>); <https://statecancerprofiles.cancer.gov/data-topics/mortality.html>), and United State Census Bureau (<https://www.census.gov/programs-surveys/acs/data.html>).

The data underlying this article will be shared on reasonable request to the corresponding author.

Supplemental Material

Supplemental material for this article is available online.

References

1. Cancer Facts & Figures for African Americans. American cancer society. <https://www.cancer.org/research/cancer-facts-statistics/cancer-facts-figures-for-african-americans.html>. Accessed July 18, 2024.
2. O'Keefe EB, Meltzer JP, Bethea TN. Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000–2010. *Front Public Health*. 2015;3. doi:10.3389/fpubh.2015.00051.
3. Ahmed AT, Welch BT, Brinjikji W, et al. Racial disparities in screening mammography in the United States: a systematic review and meta-analysis. *J Am Coll Radiol*. 2017;14(2): 157-165.e9. doi:10.1016/j.jacr.2016.07.034.
4. Grubbs SS, Polite BN, Carney J, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. *J Clin Oncol*. 2013;31(16):1928-1930. doi:10.1200/JCO.2012.47.8412.
5. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. *CA Cancer J Clin*. 2019;69(3):211-233. doi:10.3322/caac.21555.
6. Zavala VA, Bracci PM, Carethers JM, et al. Cancer health disparities in racial/ethnic minorities in the United States. *Br J Cancer*. 2021;124(2):315-332. doi:10.1038/s41416-020-01038-6.
7. Hunt B, Balachandran B. Black:White disparities in lung cancer mortality in the 50 largest cities in the United States. *Cancer Epidemiol*. 2015;39(6):908-916. doi:10.1016/j.canep.2015.10.003.
8. Whitman S, Orsi J, Hurlbert M. The racial disparity in breast cancer mortality in the 25 largest cities in the United States. *Cancer Epidemiol*. 2012;36(2):e147-e151. doi:10.1016/j.canep.2011.10.012.
9. Benjamins MR, Hunt BR, Raleigh SM, Hirschtick JL, Hughes MM. Racial disparities in prostate cancer mortality in the 50 largest US cities. *Cancer Epidemiol*. 2016;44:125-131. doi:10.1016/j.canep.2016.07.019.
10. Hayanga AJ, Zeliadt SB, Backhus LM. Residential segregation and lung cancer mortality in the United States. *JAMA Surg*. 2013;148(1):37. doi:10.1001/jamasurgery.2013.408.
11. Poulson MR, Beaulieu-Jones BR, Kenzik KM, et al. Residential racial segregation and disparities in breast cancer presentation, treatment, and survival. *Ann Surg*. 2021;273(1):3-9. doi:10.1097/SLA.0000000000004451.
12. Landrine H, Corral I, Lee JGL, Efrid JT, Hall MB, Bess JJ. Residential segregation and racial cancer disparities: a systematic review. *J Racial Ethn Health Disparities*. 2017;4(6): 1195-1205. doi:10.1007/s40615-016-0326-9.

13. Yang W, Williams JH, Hogan PF, et al. Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage. *J Oncol Pract.* 2014;10(1):39-45. doi:[10.1200/JOP.2013.001319](https://doi.org/10.1200/JOP.2013.001319).
14. Siddappa Malleshappa SK, Giri S, Patel S, et al. Overall survival based on oncologist density in the United States: a retrospective cohort study. Kim IY, ed. *PLoS One.* 2021. 16(5):e0250894. doi:[10.1371/journal.pone.0250894](https://doi.org/10.1371/journal.pone.0250894)
15. Camacho FT, Tan X, Alcalá HE, Shah S, Anderson RT, Balkrishnan R. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors. *Medicine (Baltimore).* 2017; 96(24):e7147. doi:[10.1097/MD.00000000000007147](https://doi.org/10.1097/MD.00000000000007147).
16. Tan X, Camacho F, Marshall VD, Donohoe J, Anderson RT, Balkrishnan R. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer. *Res Soc Adm Pharm.* 2017;13(4):796-810. doi:[10.1016/j.sapharm.2016.08.004](https://doi.org/10.1016/j.sapharm.2016.08.004).
17. National cancer institute state cancer profiles. Accessed October 1, 2020. <https://statecancerprofiles.cancer.gov/>
18. Aneja S, Yu JB. The impact of county-level radiation oncologist density on prostate cancer mortality in the United States. *Prostate Cancer Prostatic Dis.* 2012;15(4):391-396. doi:[10.1038/pcan.2012.28](https://doi.org/10.1038/pcan.2012.28).
19. Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. Urologist density and county-level urologic cancer mortality. *J Clin Oncol.* 2010;28(15):2499-2504. doi:[10.1200/JCO.2009.26.9597](https://doi.org/10.1200/JCO.2009.26.9597).
20. Aneja S, Aneja S, Bordeaux JS. Association of increased dermatologist density with lower melanoma mortality. *Arch Dermatol.* 2012;148(2):174. doi:[10.1001/archdermatol.2011.345](https://doi.org/10.1001/archdermatol.2011.345).
21. Farmer MM, Ferraro KF. Are racial disparities in health conditional on socioeconomic status? *Soc Sci Med.* 2005;60(1): 191-204. doi:[10.1016/j.socscimed.2004.04.026](https://doi.org/10.1016/j.socscimed.2004.04.026).
22. Assari S. Health disparities due to diminished return among Black Americans: public policy solutions. *Soc Issues Policy Rev.* 2018;12(1):112-145. doi:[10.1111/sipr.12042](https://doi.org/10.1111/sipr.12042).
23. Pallok K, De Maio F, Ansell DA. Structural racism — a 60-year-old Black woman with breast cancer. *N Engl J Med.* 2019; 380(16):1489-1493. doi:[10.1056/NEJMp1811499](https://doi.org/10.1056/NEJMp1811499).
24. Artiga S, Hill L, Orgera K, Damico A. *Health Coverage by Race and Ethnicity, 2010-2019*. San Francisco, CA, USA: Kaiser Family Foundation. Published 2021. <https://www.kff.org/racial-equity-and-health-policy/issue-brief/health-coverage-by-race-and-ethnicity/>. Accessed December 1, 2022.
25. Thirukumaran CP, Glance LG, Cai X, Balkissoon R, Mesfin A, Li Y. Performance of safety-net hospitals in year 1 of the comprehensive care for joint replacement model. *Health Aff (Millwood).* 2019;38(2):190-196. doi:[10.1377/hlthaff.2018.05264](https://doi.org/10.1377/hlthaff.2018.05264).
26. Marshall L, Harbin V, Hooker J, Oswald J, Cummings L. Safety net hospital performance on National quality of care process measures. *J Healthc Qual.* 2012;34(2):21-31. doi:[10.1111/j.1945-1474.2011.00186.x](https://doi.org/10.1111/j.1945-1474.2011.00186.x).
27. Sarkar RR, Courtney PT, Bachand K, et al. Quality of care at safety-net hospitals and the impact on pay-for-performance reimbursement. *Cancer.* 2020;126(20):4584-4592. doi:[10.1002/cncr.33137](https://doi.org/10.1002/cncr.33137).
28. Popescu I, Schrag D, Ang A, Wong M. Racial/ethnic and socioeconomic differences in colorectal and breast cancer treatment quality: the role of physician-level variations in care. *Med Care.* 2016;54(8):780-788. doi:[10.1097/MLR.0000000000000561](https://doi.org/10.1097/MLR.0000000000000561).
29. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat Blacks and whites. *N Engl J Med.* 2004;351(6):575-584. doi:[10.1056/NEJMs040609](https://doi.org/10.1056/NEJMs040609).
30. Esnaola NF, Ford ME. Racial differences and disparities in cancer care and outcomes. *Surg Oncol Clin N Am.* 2012;21(3): 417-437. doi:[10.1016/j.soc.2012.03.012](https://doi.org/10.1016/j.soc.2012.03.012).
31. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. *N Engl J Med.* 1999; 341(16):1198-1205. doi:[10.1056/NEJM199910143411606](https://doi.org/10.1056/NEJM199910143411606).
32. Landon BE, Onnela JP, Meneades L, O'Malley AJ, Keating NL. Assessment of racial disparities in primary care physician specialty referrals. *JAMA Netw Open.* 2021;4(1):e2029238. doi:[10.1001/jamanetworkopen.2020.29238](https://doi.org/10.1001/jamanetworkopen.2020.29238).
33. Cai C, Gaffney A, McGregor A, et al. Racial and ethnic disparities in outpatient visit rates across 29 specialties. *JAMA Intern Med.* 2021;181(11):1525. doi:[10.1001/jamainternmed.2021.3771](https://doi.org/10.1001/jamainternmed.2021.3771).
34. Schpero WL, Morden NE, Sequist TD, Rosenthal MB, Gottlieb DJ, Colla CH. For selected services, blacks and hispanics more likely to receive low-value care than whites. *Health Aff (Millwood).* 2017;36(6):1065-1069. doi:[10.1377/hlthaff.2016.1416](https://doi.org/10.1377/hlthaff.2016.1416).
35. Dimick J, Ruhter J, Sarrazin MV, Birkmeyer JD. Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions. *Health Aff (Millwood).* 2013; 32(6):1046-1053. doi:[10.1377/hlthaff.2011.1365](https://doi.org/10.1377/hlthaff.2011.1365).
36. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. *J Clin Oncol.* 2018;36(1):25-33. doi:[10.1200/JCO.2017.74.2049](https://doi.org/10.1200/JCO.2017.74.2049).
37. Moses KA, Orom H, Brasel A, Gaddy J, Underwood W. Racial/ethnic disparity in treatment for prostate cancer: does cancer severity matter? *Urology.* 2017;99:76-83. doi:[10.1016/j.urology.2016.07.045](https://doi.org/10.1016/j.urology.2016.07.045).
38. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. *JAMA Oncol.* 2016;2(3):322. doi:[10.1001/jamaoncol.2015.3856](https://doi.org/10.1001/jamaoncol.2015.3856).
39. Griggs JJ, Culakova E, Sorbero MES, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. *J Clin Oncol.* 2007;25(18):2522-2527. doi:[10.1200/JCO.2006.10.2749](https://doi.org/10.1200/JCO.2006.10.2749).
40. Obrochta CA, Murphy JD, Tsou MH, Thompson CA. Disentangling racial, ethnic, and socioeconomic disparities in treatment for colorectal cancer. *Cancer Epidemiol Biomarkers Prev.* 2021;30(8):1546-1553. doi:[10.1158/1055-9965.EPI-20-1728](https://doi.org/10.1158/1055-9965.EPI-20-1728).

41. McBride RB, Lebwohl B, Hershman DL, Neugut AI. Impact of socioeconomic status on extent of lymph node dissection for colon cancer. *Cancer Epidemiol Biomarkers Prev.* 2010;19(3):738-745. doi:[10.1158/1055-9965.EPI-09-1086](https://doi.org/10.1158/1055-9965.EPI-09-1086).
42. Morris AM, Billingsley KG, Hayanga AJ, Matthews B, Baldwin LM, Birkmeyer JD. Residual treatment disparities after oncology referral for rectal cancer. *JNCI J Natl Cancer Inst.* 2008;100(10):738-744. doi:[10.1093/jnci/djn145](https://doi.org/10.1093/jnci/djn145).
43. Rhoads KF, Cullen J, Ngo JV, Wren SM. Racial and ethnic differences in lymph node examination after colon cancer resection do not completely explain disparities in mortality. *Cancer.* 2012;118(2):469-477. doi:[10.1002/cncr.26316](https://doi.org/10.1002/cncr.26316).
44. AACR Cancer Disparities Progress Report. American Association for Cancer Research. CancerDisparitiesProgressReport.org.
45. Williams DR. Stress and the mental health of populations of color: advancing our understanding of race-related stressors. *J Health Soc Behav.* 2018;59(4):466-485. doi:[10.1177/0022146518814251](https://doi.org/10.1177/0022146518814251).
46. DesRoches CM, Barrett KA, Harvey BE, et al. The results are only as good as the sample: assessing three national physician sampling frames. *J Gen Intern Med.* 2015;30(S3):595-601. doi:[10.1007/s11606-015-3380-9](https://doi.org/10.1007/s11606-015-3380-9).
47. American Society of Clinical Oncology (ASCO). *Key Trends in Tracking Supply of and Demand for Oncologists*. Alexandria, VA, USA. <https://society.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2018-ASCO-Workforce-Information-System.pdf>. (2018).
48. Hicks-Courant K. Bringing gynecologic cancer care closer to patients. *Penn LDI*. Published January 13, 2021. <https://ldi.upenn.edu/our-work/research-updates/bringing-gynecologic-cancer-care-closer-to-patients/>. Accessed August 6, 2021.
49. Kirkwood MK, Hanley A, Bruinooge SS, et al. The state of oncology practice in America, 2018: results of the ASCO practice census Survey. *J Oncol Pract.* 2018;14(7):e412-e420. doi:[10.1200/JOP.18.00149](https://doi.org/10.1200/JOP.18.00149).
50. DeRouen MC, Canchola AJ, Thompson CA, et al. Incidence of lung cancer among never-smoking Asian American, native Hawaiian, and pacific Islander females. *JNCI J Natl Cancer Inst.* 2022;114(1):78-86. doi:[10.1093/jnci/djab143](https://doi.org/10.1093/jnci/djab143).